# Cellemedy

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellemedy

- Industry: Pharmaceuticals
- Headquarters: Seongnam-si, South Korea
- Website: www.cellemedy.com/
- Total disclosed funding: $3.7M
- Latest round: Seed (Dec 1, 2020)
- Investors on record: 3

## About

Based in Gyeonggi-do, South Korea, and founded in 2016, Cellemedy Inc. specializes in pioneering therapeutic proteins aimed at revolutionizing antibody treatments, particularly in oncology, to enhance immunotherapy efficacy.Founded in Seongnam, South Korea, Cellemedy Inc. focuses on the development of innovative therapeutic proteins. The company has maintained a consistent strategy without significant pivots. Details about the founder's prior ventures are not available. The company has engaged in partnerships for funding, contributing to its growth.Cellemedy Inc. specializes in the development of next-generation therapeutic proteins aimed at transforming conventional antibody treatments. Their innovative platform, T-sphaera??, is designed to target multiple pathways in oncology, enhancing the efficacy of immunotherapy treatments. The company’s drug conjugate pipeline focuses on providing advanced solutions for cancer care, with a commitment to replacing existing therapies with more effective alternatives. These products are intended for use primarily in the oncology sector, addressing significant unmet needs in cancer treatment. Cellemedy targets healthcare providers and institutions, particularly in markets such as North America and Europe, where there is a strong demand for innovative biopharmaceuticals.Cellemedy operates on a business model that involves partnerships and collaborations with pharmaceutical firms and healthcare institutions, facilitating the distribution of its therapeutic proteins. Revenue generation stems from licensing agreements, research collaborations, and direct sales of their proprietary products such as those under the T-sphaera?? platform. Given the nature of biotechnology, transactions are structured to support long-term partnerships, where clients may engage in joint ventures or clinical trials to validate the efficacy of Cellemedy’s offerings. The company is positioned to capitalize on the growing need for advanced cancer therapies, with specific pricing plans for their products reflecting the premium nature of biopharmaceutical innovations.

## Funding rounds

- Seed, Dec 1, 2020, $3.7M — IMM Investment, DAYLI Partners, Stonebridge Ventures

## Investors

- IMM Investment (https://capitalatlas.ai/funds/imm-investment) — Seed
- DAYLI Partners (https://capitalatlas.ai/funds/dayli-partners) — Seed
- Stonebridge Ventures — Seed